Characterization of Recurrence Patterns and Healthcare Resource Utilization for Patients With Stage II Cutaneous Melanoma in Spain: Metheor Study

Speaker(s)

Puig S1, Boada A2, Diago A3, Samaniego E4, Fernández de Misa Cabrera R5, Ortiz Romero PL6, Moreno S7, Ferrándiz L8, Flórez Á9, Vílchez-Márquez F10, Ostios-García L11, Vilanova Larena D12, Nagore E13
1Hospital Clínic de Barcelona, Barcelona, Barcelona, Spain, 2Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, 3Hospital Universitario Miguel Servet, Zaragoza, Zaragoza, Spain, 4Complejo Asistencial Universitario de León, León, León, Spain, 5Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Santa Cruz de Tenerife, Spain, 6Hospital Universitario 12 de Octubre, Madrid, Spain, 7Hospital Arnau de Vilanova Lleida, Lleida, Lleida, Spain, 8Hospital Virgen de la Macarena, Sevilla, Sevilla, Spain, 9Complejo Hospitalario Universitario de Pontevedra (CHUP), Pontevedra, Pontevedra, Spain, 10Hospital Virgen de las Nieves, Granada, Granada, Spain, 11Bristol Myers Squibb España, Madrid, Madrid, Spain, 12Bristol Myers Squibb Company, Madrid, M, Spain, 13Instituto Valenciano de Oncología (IVO), Valencia, Valencia, Spain

Presentation Documents

OBJECTIVES: In 2023, more than 7,000 cases of cutaneous melanoma (CM) were diagnosed in Spain (15% at stage II), and more than 1,000 deaths were reported. Survival rates are lower for patients with IIB-C CM than those with stage IIIB disease. Surgical excision is the standard of care for patients with stage II CM; given the results of recent phase III trials, anti-PD1 adjuvant therapy has recently been approved for those with stage IIB-C. This study describes the recurrence patterns, healthcare resource utilization (HCRU), and costs associated with treating patients with stage II CM.

METHODS: Observational, multi-center (n=11 sites), retrospective study conducted in Spain. Adult patients diagnosed with stage II primary CM between Jan 2013 and Dec 2017, with a 5-year minimum follow-up, were included.

RESULTS: 324 patients were included, 52.2% women, mean age 61.3 years, stage at diagnosis: IIA (44.4%) and IIB/IIC (56.6%). Over follow up, 90 patients (27.8%) had at least one recurrence (54.4% recurred at stage IV). After first recurrence, 57% of patients underwent surgery, and 71.6% received systemic treatment (40% anti-PD1, 18% BRAF/MEK inhibitors, 11% anti-PD1/CTLA4 combination, and 31% other treatments). 5-year recurrence-free survival for stages IIA and for IIB/C was 74.5% and 63.7% respectively. Overall, after first recurrence, both the annual HRCU rates (visits and tests) and annualized costs (test, visits and treatment) increased 251% and 941% respectively. The annual HCRU rates before/after first recurrence were 7.1/24.5 (visits) and 7.6/20.0 (tests). The annualized costs before/after first recurrence were €5,254/€56,969 (€1,267/€4,621 tests; €1,599/€11,027 visits; €2,388/€41,320 treatment).

CONCLUSIONS: This study highlights the need to implement monitoring and treatment strategies in order to reduce the risk of recurrence in patients with CM. In addition to the importance of improving patient outcomes, HCRU and costs increase significantly after first recurrence of stage II CM.

Code

EE158

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology